title: Treatment of canine Alopecia X with trilostane.
abstract: Sixteen Pomeranians and eight miniature poodles presenting with clinical signs of alopecia X, elevated blood concentrations of 17-hydroxyprogesterone post stimulation with adrenocorticotropic hormone and increased urinary cortisol/creatinine ratios were treated with trilostane, a competitive inhibitor of 3beta-hydroxysteroid dehydrogenase. Trilostane was given once or twice daily at a mean dose of 10.85 mg kg(-1) day(-1). Adrenal function was evaluated with a follow-up of 28 months in the Pomeranians and 33 months in the miniature poodles. Treatment with trilostane led to complete hair re-growth in 85% of the Pomeranians and in all of the miniature poodles within 4 to 8 weeks. No adverse events attributed to treatment with trilostane were recognized. The hair re-growth might have been the result of a down-regulation of adrenal steroids and/or of the noncompetitive inhibition of the oestrogen receptors at the hair follicle level.
authors.affiliation: Department of Veterinary Clinical Sciences, Royal Veterinary College, University of London, Hawkshead Campus, North Mymms, Herts, UK. cerundol@vet.upenn.edu
authors.forename: Rosario
authors.initials: R
authors.lastname: Cerundolo
authors.forename: David H
authors.initials: DH
authors.lastname: Lloyd
authors.forename: Angelo
authors.initials: A
authors.lastname: Persechino
authors.forename: Helen
authors.initials: H
authors.lastname: Evans
authors.forename: Andria
authors.initials: A
authors.lastname: Cauvin
mesh_terms: D019326:17-alpha-Hydroxyprogesterone / Q000097:blood; D015096:3-Hydroxysteroid Dehydrogenases / Q000037:antagonists & inhibitors*; D000284:Administration, Oral; D000324:Adrenocorticotropic Hormone; D000505:Alopecia / Q000188:drug therapy / Q000662:veterinary*; D000818:Animals; D013196:Dihydrotestosterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004283:Dog Diseases / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D010375:Pedigree; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D004791:Enzyme Inhibitors; D013196:Dihydrotestosterone; D019326:17-alpha-Hydroxyprogesterone; D000324:Adrenocorticotropic Hormone; D015096:3-Hydroxysteroid Dehydrogenases; C009954:trilostane; D006854:Hydrocortisone